Abstract
ARIAD Pharmaceuticals Inc is developing intravenous and oral formulations of AP-23573, a rapamycin analog and inhibitor of mTOR (mammalian target of rapamycin) that blocks the proliferation and migration of vascular smooth muscle cells, for the potential treatment of cancer, including solid and hematological forms.
MeSH terms
-
Animals
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Humans
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Protein Kinases / metabolism*
-
Sirolimus / adverse effects
-
Sirolimus / analogs & derivatives*
-
Sirolimus / chemical synthesis
-
Sirolimus / pharmacokinetics
-
Sirolimus / pharmacology*
-
Sirolimus / therapeutic use
-
Structure-Activity Relationship
-
TOR Serine-Threonine Kinases
Substances
-
Antineoplastic Agents
-
ridaforolimus
-
Protein Kinases
-
MTOR protein, human
-
TOR Serine-Threonine Kinases
-
Sirolimus